Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
Julphar
Chubb
Farmers Insurance
Fish and Richardson
Cipla
Harvard Business School
QuintilesIMS
Dow

Generated: October 23, 2017

DrugPatentWatch Database Preview

INVEGA Drug Profile

« Back to Dashboard

What is the patent landscape for Invega, and what generic Invega alternatives are available?

Invega is a drug marketed by Janssen Pharms and is included in three NDAs. There are three patents protecting this drug.

The generic ingredient in INVEGA is paliperidone palmitate. There are thirty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

Summary for Tradename: INVEGA

US Patents:0
Applicants:1
NDAs:3
Suppliers / Packagers: see list5
Bulk Api Vendors: see list76
Clinical Trials: see list18
Patent Applications: see list275
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:INVEGA at DailyMed

Pharmacology for Tradename: INVEGA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-001May 18, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-005Jul 31, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-002May 18, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-005Jul 31, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-006Aug 26, 2008ABRXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-004Jul 31, 2009RXYesYes► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-003May 18, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-003Dec 19, 2006ABRXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INVEGA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-006Aug 26, 2008► Subscribe► Subscribe
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-004Dec 19, 2006► Subscribe► Subscribe
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-002Dec 19, 2006► Subscribe► Subscribe
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-001Dec 19, 2006► Subscribe► Subscribe
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-003Dec 19, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
McKinsey
Healthtrust
Federal Trade Commission
Covington
Argus Health
Johnson and Johnson
Cantor Fitzgerald
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot